EPO Patent Bulletin - Therapeutics (A61P)

Use of Chimeric Antigen Receptor-Modified T Cells to Treat Cancer

The European Patent Office granted Patent EP3660029A1 to The Trustees of the University of Pennsylvania covering chimeric antigen receptor (CAR)-modified T cells for cancer treatment. The patent names inventors Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, and Michael C. Milone. The patent covers methods for treating cancer using CAR-modified T cells, with designations extending across 35 European states.

Methods for Using Low-Dose Colchicine After Myocardial Infarction (EP3821909A1)

The European Patent Office published application EP3821909A1, titled 'Methods for Using Low-Dose Colchicine After Myocardial Infarction.' The application, filed by Institut de Cardiologie de Montréal, claims methods of treating patients with low-dose colchicine following myocardial infarction. The published application covers 38 designated European states.

INHIBITORS OF TRPC6 - Boehringer Ingelheim International GmbH

The European Patent Office published patent application EP3752503A1 for TRPC6 inhibitors assigned to Boehringer Ingelheim International GmbH. The patent covers therapeutic compounds for cardiovascular, respiratory, and neurological applications. The application designates all EPC contracting states including Germany, France, United Kingdom, Italy, and Spain.

Novel Anti-inflammatory Compounds - EP3759089A1

The European Patent Office published patent application EP3759089A1 for novel anti-inflammatory compounds developed by Inflazome Limited. The patent covers compounds classified under C07D 401/12 with therapeutic applications (A61P 29/00). Validated in designated contracting states including Germany, France, United Kingdom, Italy, Spain, and other EU member states.

EP3759090A1 Novel Therapeutic Compounds by Inflazome Limited

The European Patent Office published patent application EP3759090A1 for novel therapeutic compounds filed by Inflazome Limited. The patent covers heterocyclic compounds with IPC classifications including C07D derivatives and A61P therapeutic activity (anti-inflammatory/analgesic). Designated states include all EU member states plus associated countries. The publication marks the grant of patent rights for these novel compounds.